{"id":426,"date":"2017-09-08T07:58:31","date_gmt":"2017-09-08T07:58:31","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=426"},"modified":"2017-09-08T07:58:31","modified_gmt":"2017-09-08T07:58:31","slug":"nota-informativa-muh-fv-92017","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2017\/09\/08\/nota-informativa-muh-fv-92017\/","title":{"rendered":"Nota Informativa MUH (FV), 9\/2017"},"content":{"rendered":"<table class=\"tablaHome\">\n<tbody>\n<tr>\n<td><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2017\/NI-MUH_FV_09-2017-brivudina-Nervinex.htm\">Brivudina (Nervinex): se recuerda que est\u00e1 contraindicada su administraci\u00f3n junto con antineopl\u00e1sicos, especialmente 5-fluoropirimidinas, debido a la interacci\u00f3n potencialmente mortal<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Brivudina (Nervinex): se recuerda que est\u00e1 contraindicada su administraci\u00f3n junto con antineopl\u00e1sicos, especialmente 5-fluoropirimidinas, debido a la interacci\u00f3n potencialmente mortal<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-426","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=426"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/426\/revisions"}],"predecessor-version":[{"id":427,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/426\/revisions\/427"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}